Chief, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin; Chief Scientific Director, Center for International Blood and Marrow Transplant Research
Hematology
Dr. Mary M. Horowitz, MD
|
|
Give Review
Mary Horowitz practices Hematology. She attended Medical College of Wisconsin. Medical College of Wisconsin is ranked 54 in research and 62 in primary care medicine Mary Horowitz is also published. She has 101 publications published. The lastest publication: "Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen:...' She accepts Medicare payments and is listed with Medicare.gov.
Publications
- Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors.
- Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen:...
- The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.
- Increasing incidence of chronic Graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
- Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplan...
- Comparison of Outcomes of Allogeneic Transplantation for CML with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan or TBI.
- Bone Marrow or Peripheral Blood for Reduced-Intensity Conditioning Unrelated Donor Transplantation.
- Exercise and Stress Management Training Prior to Hematopoietic Cell Transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902.
- HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation.
- Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2014.
- Phase III clinical trial steroids/mycophenolate mofetil vs steroids/placebo as therapy for Acute graft-versus-host disease: BMT CTN 0802.
- Non-permissive -DPB1 mismatch among otherwise HLA-matched donor-recipient pairs results in increased overall mortality after myeloablative unrelated allogeneic hematop...
- Multicenter Biologic Assignment Trial Comparing Reduced-Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patien...
- Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome af...
- Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation.
- Validation and refinement of the Disease risk index for allogeneic stem cell transplantation: a study from the CIBMTR.
- Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts.
- Graft-versus-host disease and survival after cord blood transplantation for Acute leukemia: a comparison of the Japanese versus Caucasian population.
- Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy.
- Better Leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI.
- Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international co...
- Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS).
- Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of EnGraftment Syndrome after Autologous Peripheral Blood Stem Cell Transplantation...
- Multiple mismatches at the low expression HLA loci DP, DQ, DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation.
- Anatomy of a Successful Practice-Changing Study: A Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group Collaboration.
- Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic...
- Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation.
- Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?
- Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in...
- Transplants for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research (CIBMTR).
- Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared to children and older adults with Acute myeloid leukemia.
- Risk factors for Acute GVHD and survival after hematopoietic cell transplantation.
- Risk factors associated with increased non-relapse mortality and with poor overall survival in children with chronic Graft-versus-host disease.
- Easy-to-Read Informed Consent Forms for Hematopoietic Cell Transplant Clinical Trials.
- Effect of stem cell source on outcomes after adult unrelated donor transplantation in severe aplastic Anemia.
- Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
- Impact of immune modulation with anti-T cell antibodies on outcomes of reduced intensity allogeneic hematopoietic cell transplantation for hematologic malignancies.
- Long-Term Survival and Late Deaths After Allogeneic Hematopoietic Cell Transplantation.
- Optimization of therapy for severe aplastic Anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on sev...
- Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning.
- Factors associated with self-reported physical and mental health after hematopoietic cell transplantation.
- Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complet...
- Access to hematopoietic stem cell transplantation: effect of race and sex.
- Re: An approach to predicting HSCT outcome using HLA-mismatch information mapped on protein structure data.
- Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid Leukemia in first chronic phase.
- Allogeneic hematopoietic cell transplant for prolymphocytic Leukemia.
- Outcome of transplantation for myelofibrosis.
- 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and ...
- Alternative donor transplantation for aplastic Anemia.
- Impending challenges in the hematopoietic stem cell transplantation physician workforce.
- Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.
- Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic Disorders: a report from the center for international ...
- Risk factors for lymphoproliferative Disorders after allogeneic hematopoietic cell transplantation.
- Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant.
- Adverse events among 2408 unrelated donors of Peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program.
- HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid Leukemia.
- The graft-versus-Leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.
- Solid cancers after allogeneic hematopoietic cell transplantation.
- Sirolimus is associated with veno-occlusive Disease of the liver after myeloablative allogeneic stem cell transplantation.
- Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid Leukemia.
- Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.
- HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from ...
- On the probability of using cord blood.
- Use of cost-effectiveness analysis to determine inventory size for a national cord blood bank.
- Lifetime probabilities of hematopoietic stem cell transplantation in the U.S.
- The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation.
- Peripheral blood grafts from unrelated donors are associated with increased Acute and chronic graft-versus-host disease without improved survival.
- Missing KIR ligands are associated with less relapse and increased Graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.
- Bone marrow transplantation for severe aplastic Anemia: a randomized controlled study of conditioning regimens.
- Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls.
- Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation.
- A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allograf...
- 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of Acute myeloid leukemia in first remiss...
- Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation.
- Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for Acute myelogenous leukemia in first rem...
- Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for Acute leukemia in children younger than 18 mon...
- Outcome of ethnic minorities with Acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
- Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for Leukemia.
- Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for Acute myelogenous leukemia predicted by KIR and HLA genotypes.
- Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study.
- Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States.
- Comparison of Graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations.
- Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation.
- Evaluation of hematopoietic stem cell donors.
- Higher mortality after allogeneic Peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cel...
- Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with Leukemia.
- Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation.
- Autologous hematopoietic stem-cell transplantation for children with Acute myeloid leukemia in first or second complete remission: a prognostic factor analysis.
- A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with...
- Autologous transplantation for diffuse aggressive non-Hodgkin Lymphoma in first relapse or second remission.
- Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular Lymphoma.
- Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for Acute and chronic leukemia by ethnicity in the United States and Canada.
- Performance of a new clinical grading system for chronic Graft-versus-host disease: a multicenter study.
- Myelodysplastic syndrome and Acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.
- Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.
- Severity of chronic Graft-versus-host disease: association with treatment-related mortality and relapse.
- Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant Diseases.
- High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Tra...
- A survey of diagnosis, management, and grading of chronic GVHD.
- Autologous stem cell transplantation for small cell lung cancer.
Schools
Medical College of Wisconsin
Procedures Preformed
- Bone Marrow Transplant
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Graft vs Host Disease
- Hodgkin's Disease
- View All
Doctors Specialties
- Oncology
- Hematology
Accepted Insurances
Education
-
Medical College of Wisconsin Affiliated Hospitals -
Medical College of Wisconsin
Hospital
-
Froedtert Memorial Lutheran Hospital
Drug Facts
| NPI NUMBER | 1356392195 | |
| NPPES Provider LastName | HOROWITZ | |
| NPPES Provider FirstName | MARY | |
| NPPES Provider ZIPCode | 532263522 | |
| NPPES Provider State | WI | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 37.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1356392195 |
| Last Name Of The Provider | HOROWITZ |
| First Name Of The Provider | MARY |
| View All |
Similar Doctors
|
Dr. Kathryn Bylow, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Gilbert C. White II, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Charles A. Bomzer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Magdalena Flejsierowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Christopher Chitambar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph A. Libnoch, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert J. Schneidewend, DO |